Your browser doesn't support javascript.
loading
P53 and PTEN expression contribute to the inhibition of EGFR downstream signaling pathway by cetuximab.
Bouali, S; Chrétien, A-S; Ramacci, C; Rouyer, M; Marchal, S; Galenne, T; Juin, P; Becuwe, P; Merlin, J-L.
Affiliation
  • Bouali S; Centre Alexis Vautrin, Unité de Biologie des Tumeurs, EA Predicther Nancy Université, Vandoeuvre-lès-Nancy cedex, France.
Cancer Gene Ther ; 16(6): 498-507, 2009 Jun.
Article in En | MEDLINE | ID: mdl-19165235
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Signal Transduction / Tumor Suppressor Protein p53 / PTEN Phosphohydrolase / ErbB Receptors / Antibodies, Monoclonal / Antineoplastic Agents Type of study: Prognostic_studies Limits: Humans / Male Language: En Journal: Cancer Gene Ther Journal subject: GENETICA MEDICA / NEOPLASIAS / TERAPEUTICA Year: 2009 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Signal Transduction / Tumor Suppressor Protein p53 / PTEN Phosphohydrolase / ErbB Receptors / Antibodies, Monoclonal / Antineoplastic Agents Type of study: Prognostic_studies Limits: Humans / Male Language: En Journal: Cancer Gene Ther Journal subject: GENETICA MEDICA / NEOPLASIAS / TERAPEUTICA Year: 2009 Document type: Article Affiliation country: Country of publication: